MELBOURNE, Australia, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”), a
molecular diagnostics company specialising in cancer genomics, and provider of BREVAGenplus®, a first-in-class,
clinically validated risk assessment test for non-hereditary breast cancer, announced today that it will transition the product’s
commercial program to an ecommerce based solution. Under the new program, the consumer will be able to initiate the testing by
accessing the Consumer Initiated Testing (CIT) platform via the Company’s U.S. subsidiary, Phenogen Sciences, Inc. website, by
visiting www.brevagenplus.com.
“Since embarking on the commercial launch of BREVAGenplus we have been steadfast in exploring the
optimal methodology to effectively market the product without comprising resources. Our recent shift to a patient self-pay
program coupled with the on-going operational strategic review served as catalysts to transform the commercial program into a pure
ecommerce system enabling us to manage in totality, a streamlined organisation that is conserving capital without comprising
commercial activities,” commented Mr. Eutillio Buccilli, Chief Executive Officer of Genetic Technologies Limited.
CIT provides testing under the guidance and management of a remote physician using guideline driven protocols to
ensure;
- A two-way patient physician relationship is established
- Appropriate informed consent is obtained
- Results are interpreted correctly
- Abnormal results are flagged responsibly and communicated in a way to drive action
- State guidelines are being met for the ordering of laboratory tests
- Next steps are provided and the individual is triaged to local care when called for
A CIT platform, complemented by direct to consumer advertising, can reach two primary audiences through various
channels and mediums. First, the patient that qualifies for the product may be reached through multiple promotional publications
and second, the healthcare provider that focuses on women’s health and the administration of better breast health. The CIT strategy
is currently used in the market by U.S. based laboratories with the patient having the ability of ordering the test through a user
friendly platform that is authorised by a licensed healthcare provider. CIT offers the inclusion of a licensed healthcare provider,
patient qualification and direct advertising channels to the targeted audiences.
In April of 2017, in an effort to simplify the customer experience, the Company switched its billing model from
a traditional reimbursement system through medical insurance providers, to a direct patient self-pay system, with a new reduced
list price of USD $349.00 per test. The rationale behind the change in the billing system was based on the recognition that gaining
adequate payment for BREVAGenplus, through a CPT miscellaneous code, had become increasingly difficult over the past few
years. Furthermore, by converting to a direct pay relationship with patients, the Company added certainty to the transaction, thus,
eliminating issues such as low levels of reimbursement, prolonged payment time, patient confusion around eligibility and financial
responsibility and poor coverage.
Under the refined commercial program, the Company will continue to provide product consulting and educational
resources to the physician and patient communities. A BREVAGenplus dedicated staff member will be available telephonically
to address incoming product specification queries and provide counsel to parties interested in learning more about the test.
About Genetic Technologies Limited
Genetic Technologies is a molecular diagnostics company that offers cancer predictive testing and assessment
tools to help physicians proactively manage patient health. The Company’s lead product, BREVAGenplus®, is a
clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus
is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans, and is directed
towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast
cancer.
The Company markets BREVAGenplus, through its U.S. subsidiary Phenogen Sciences Inc., to healthcare
professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and
breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com.
Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer
test. For more information, please visit www.gtgcorporate.com
Safe Harbor Statement
Any statements in this press release that relate to the Company's expectations are forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of
1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws,
including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may
involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from
expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with
the SEC.
FOR FURTHER INFORMATION PLEASE CONTACT Mr. Eutillio Buccilli Executive Director & Chief Executive Officer Genetic Technologies Limited + 61 3 8412 7050 Jason Wong (USA) Blueprint Life Science Group + 1 (415) 375 3340, Ext. 4
